Achieve Life Sciences Total Assets | ACHV

Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.

Main categories of assets
Current assets (used within one year):

Cash and cash equivalents
Accounts receivable (amounts owed by customers)
Inventory of goods, raw materials, and supplies
Short-term investments

Non-current assets (used for more than one year):

Fixed assets (buildings, machinery, equipment)
Intangible assets (brands, patents, software)
Long-term investments
Goodwill (reputational value from mergers)

Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.

Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.

Annual Total Assets Achieve Life Sciences

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008
41.8 M	38.6 M	19.4 M	30 M	47.5 M	40.3 M	21.1 M	19.1 M	9.89 M	27.5 M	58.2 M	56.3 M	55.7 M	82 M	68 M	89.9 M	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
89.9 M	9.89 M	44.1 M

Quarterly Total Assets Achieve Life Sciences

2026-Q2	2026-Q1	2025-Q4	2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
41.8 M	33.1 M	38.6 M	52 M	58.9 M	27.4 M	38.6 M	47.9 M	64.8 M	70 M	19.4 M	24.3 M	28.9 M	20.8 M	30 M	23.7 M	34 M	40.6 M	47.5 M	37.8 M	45.6 M	33.7 M	40.3 M	40.3 M	40.3 M	40.3 M	21.1 M	21.1 M	21.1 M	21.1 M	19.1 M	19.1 M	19.1 M	19.1 M	9.89 M	9.89 M	9.89 M	9.89 M	3.81 M	3.81 M	27.5 M	27.5 M	58.2 M	58.2 M	58.2 M	58.2 M	56.3 M	56.3 M	56.3 M	56.3 M	55.7 M	55.7 M	55.7 M	55.7 M	82 M	82 M	82 M	82 M	68 M	68 M	68 M	68 M

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
82 M	3.81 M	41.4 M

Total Assets of other stocks in the Biotechnology industry

Issuer	Total Assets	Price	% 24h	Market Cap	Country
Celsion Corporation CLSN	12.3 M	-	-6.63 %	$ 13.9 M	USA
FSD Pharma HUGE	11.2 M	-	5743.5 %	$ 69.7 M	Canada
Qilian International Holding Group Limited QLI	434 M	-	-6.08 %	$ 184 M	China
Happiness Biotech Group Limited HAPP	35.6 M	-	1.35 %	$ 17.8 M	China
Synthetic Biologics SYN	38.2 M	-	1.32 %	$ 16.2 M	USA
Dynavax Technologies Corporation DVAX	986 M	-	-	$ 2.02 B	USA
BioXcel Therapeutics BTAI	44.9 M	$ 1.19	5.31 %	$ 14.5 M	USA
Burford Capital Limited BUR	6.64 B	$ 4.37	0.23 %	$ 958 M	Britain
I-Mab IMAB	2.61 B	-	-	$ 866 M	China
BeyondSpring BYSI	25.9 M	$ 0.84	34.27 %	$ 34.5 M	USA
Corner Growth Acquisition Corp. COOL	1.97 M	-	-0.89 %	$ 114 M	USA
AgeX Therapeutics AGE	6.95 M	-	-10.17 %	$ 12.2 K	USA
Alexion Pharmaceuticals, Inc. ALXN	18.1 B	-	-	$ 40.3 B	USA
Genfit SA GNFT	151 M	-	2.54 %	$ 160 B	France
Biophytis SA BPTS	12 M	-	-13.47 %	$ 169 M	France
Cerus Corporation CERS	222 M	$ 2.98	4.93 %	$ 568 M	USA
Compugen Ltd. CGEN	157 M	$ 2.41	4.17 %	$ 225 M	Israel
CureVac N.V. CVAC	803 M	-	-	$ 867 M	Germany
EyeGate Pharmaceuticals, Inc. EYEG	15.2 M	-	-1.52 %	$ 24.7 M	USA
Athira Pharma ATHA	92.2 M	-	-	$ 269 M	USA
BiondVax Pharmaceuticals Ltd. BVXV	99.6 M	-	0.74 %	$ 768 M	Israel
Abcam plc ABCM	1.06 B	-	-	$ 4.9 B	Britain
Завод ДИОД DIOD	1.4 B	-	-	-	Russia
Galera Therapeutics GRTX	7.2 M	-	-32.59 %	$ 7.61 M	USA
Midatech Pharma plc MTP	18.2 M	-	-18.52 %	$ 27.3 M	Britain
Hepion Pharmaceuticals HEPA	3.07 M	-	-18.79 %	$ 39.3 K	USA
ARCA biopharma ABIO	489 M	-	1052.0 %	$ 415 M	USA
MorphoSys AG MOR	2.03 B	-	2.43 %	$ 254 M	Germany
Champions Oncology CSBR	27 M	$ 5.1	2.63 %	$ 70.5 M	USA
Affimed N.V. AFMD	97.2 M	-	-34.95 %	$ 21.5 M	Germany
AnPac Bio-Medical Science Co., Ltd. ANPC	40.5 M	-	-1.58 %	$ 28.1 M	China
Celyad Oncology SA CYAD	19.7 M	-	-	$ 12.5 M	Belgium
Adial Pharmaceuticals ADIL	6.67 M	$ 3.98	1.86 %	$ 2.66 M	USA
Generation Bio Co. GBIO	231 M	-	-	$ 344 M	USA
Akero Therapeutics AKRO	826 M	-	-	$ 3.67 B	USA
AnaptysBio ANAB	364 M	$ 58.47	4.37 %	$ 1.68 B	USA
Anika Therapeutics ANIK	190 M	$ 21.5	1.56 %	$ 308 M	USA
Cyclacel Pharmaceuticals CYCCP	8.18 M	-	-4.36 %	$ 27 M	USA
Gracell Biotechnologies GRCL	1.66 B	-	-	$ 3.37 B	China
Aurinia Pharmaceuticals AUPH	752 M	$ 15.47	1.91 %	$ 2.08 B	Canada
GlycoMimetics GLYC	240 M	-	9357.83 %	$ 1.01 B	USA
Aeterna Zentaris AEZS	21.4 M	-	5.93 %	$ 314 M	Canada
AVROBIO AVRO	261 M	-	1083.1 %	$ 745 M	USA
BeiGene, Ltd. BGNE	8.19 B	-	0.49 %	$ 251 B	Cayman-islands
Bicycle Therapeutics plc BCYC	718 M	$ 3.9	0.24 %	$ 270 M	Britain
Beam Therapeutics BEAM	1.48 B	$ 26.75	0.91 %	$ 2.65 B	USA
AIkido Pharma AIKI	113 M	-	1.93 %	$ 17.4 M	USA
Aeglea BioTherapeutics AGLE	778 M	-	-	$ 1.01 B	USA
BioMarin Pharmaceutical BMRN	7.59 B	$ 67.36	0.99 %	$ 12.9 B	USA
Aptose Biosciences APTO	10 M	-	-45.71 %	$ 1.2 M	Canada